India buys 300,000 doses of Remdesivir from Egypt

(Shutterstock)
Short Url
  • The shipments came as part of Egypt’s support and solidarity with friendly countries

CAIRO: India has bought 300,000 doses of the Remdesivir drug from Egypt’s Eva Pharma company as it grapples with a coronavirus crisis.

The Indian Embassy in Cairo on Monday signed an agreement to procure 300,000 doses of the drug that is used to treat coronavirus infections.

The signing ceremony was attended by Indian envoy Ajit Gupte and Riad Armanious, CEO of Eva Pharma.

It was held at the embassy of India in Cairo, with the embassy acting on behalf of India’s Ministry of Health and Family Welfare.

Gupte thanked Egyptian President Abdel Fattah El-Sisi and Prime Minister Mostafa Madbouly for directing relevant Egyptian authorities to cooperate with India in the medical emergency.

He expressed confidence in Remdesivir to effectively heal of tens of thousands of coronavirus patients.

Gupte praised the keenness of the Egyptian state and Egyptian national institutions to support India.

He said that the sale of the drug will play a “crucial” role in India’s fight against coronavirus. The country is expected to receive doses quickly over the next few days, according to the Middle East News Agency.

Armanious affirmed his confidence in Remdesivir speeding up the recovery of Indian coronavirus patients.

He said that the drug prevents the virus from reproducing inside the cells of the human body and stops its spread, which will reduce death rates in India.

Armanious added that the drug has achieved “great success” across several continents after it was exported to a large number of countries.

Meanwhile, on Sunday, Egypt’s Ministry of Health and Population sent three military aircraft to India loaded with large quantities of medical aid.

The shipments came as part of Egypt’s support and solidarity with friendly countries, and implements the directives of El-Sisi, an official statement said.

India is experiencing a second wave of COVID-19, with high rates of infections and deaths amid an acute shortage of medicine, medical supplies, and prevention and protection tools.